SARS-CoV-2 evolution in a patient with secondary B-cell immunodeficiency : A clinical case
The article highlights the course of long-term SARS-CoV-2 infection in a patient with a secondary immunodeficiency developed with B-cell-depleting therapy of the underlying disease. Analysis of the intrapatient virus evolution revealed an inpatient S:G75A mutation that alters the 72GTNGTKR78 motif of the S-protein, with a possible role in binding to alternative cellular receptors. Therapy with a ready-made COVID-19-globulin preparation (native human immunoglobulin G (IgG) derived from the plasma of convalescent COVID-19-patients) resulted in rapid improvement of the patient's condition, fast, and stable elimination of the virus, and passive immunization of the patient for at least 30 days. The results suggest the use of products containing neutralizing antibodies opens new prospects for treatment algorithms for patients with persistent coronavirus infection, as well as for passive immunization schemes for patients with a presumably reduced specific response to vaccination.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Human vaccines & immunotherapeutics - 18(2022), 6 vom: 30. Nov., Seite 2101334 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mukhina, Olgo A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.12.2022 Date Revised 21.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/21645515.2022.2101334 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344338509 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344338509 | ||
| 003 | DE-627 | ||
| 005 | 20231226205055.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/21645515.2022.2101334 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1147.xml |
| 035 | |a (DE-627)NLM344338509 | ||
| 035 | |a (NLM)35914217 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mukhina, Olgo A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 evolution in a patient with secondary B-cell immunodeficiency |b A clinical case |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2022 | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The article highlights the course of long-term SARS-CoV-2 infection in a patient with a secondary immunodeficiency developed with B-cell-depleting therapy of the underlying disease. Analysis of the intrapatient virus evolution revealed an inpatient S:G75A mutation that alters the 72GTNGTKR78 motif of the S-protein, with a possible role in binding to alternative cellular receptors. Therapy with a ready-made COVID-19-globulin preparation (native human immunoglobulin G (IgG) derived from the plasma of convalescent COVID-19-patients) resulted in rapid improvement of the patient's condition, fast, and stable elimination of the virus, and passive immunization of the patient for at least 30 days. The results suggest the use of products containing neutralizing antibodies opens new prospects for treatment algorithms for patients with persistent coronavirus infection, as well as for passive immunization schemes for patients with a presumably reduced specific response to vaccination | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a B-cell depletion | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Immunodeficiency | |
| 650 | 4 | |a Rituximab | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a convalescent plasma | |
| 650 | 4 | |a coronavirus evolution | |
| 650 | 4 | |a human immunoglobulin | |
| 650 | 4 | |a normal human intravenous immunoglobulin | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 700 | 1 | |a Fomina, Daria S |e verfasserin |4 aut | |
| 700 | 1 | |a Parshin, Vasiliy V |e verfasserin |4 aut | |
| 700 | 1 | |a Gushchin, Vladimir A |e verfasserin |4 aut | |
| 700 | 1 | |a Dolzhikova, Inna V |e verfasserin |4 aut | |
| 700 | 1 | |a Shchetinin, Alexey M |e verfasserin |4 aut | |
| 700 | 1 | |a Chudakov, Dmitriy M |e verfasserin |4 aut | |
| 700 | 1 | |a Alekseeva, Evgeniia |e verfasserin |4 aut | |
| 700 | 1 | |a Korostin, Dmitriy |e verfasserin |4 aut | |
| 700 | 1 | |a Bazykin, Georgii A |e verfasserin |4 aut | |
| 700 | 1 | |a Klink, Galya |e verfasserin |4 aut | |
| 700 | 1 | |a Logunov, Denis Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Lysenko, Maryana A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Human vaccines & immunotherapeutics |d 2012 |g 18(2022), 6 vom: 30. Nov., Seite 2101334 |w (DE-627)NLM21576823X |x 2164-554X |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:6 |g day:30 |g month:11 |g pages:2101334 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/21645515.2022.2101334 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 6 |b 30 |c 11 |h 2101334 | ||